Efficacy and Safety Study of Argatroban to Treat Heparin-Induced Thrombocytopenia

PHASE3CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

July 31, 2006

Study Completion Date

September 30, 2006

Conditions
Heparin-Induced Thrombocytopenia
Interventions
DRUG

argatroban

beginning dose: 0.7microgram/kg/H

Trial Locations (20)

1138655

The University of Tokyo Hospital, Tokyo

1528902

National Hospital Organization Tokyo Medical Center, Tokyo

1608582

Keio University Hospital, Tokyo

1830003

Sakakibara Memorial Hospital, Fuchū

2591193

Tokai University Hospital, Isehara

4600001

National Hospital Organization Nagoya Medical Center, Nagoya

4668560

Nagoya University Hospital, Nagoya

4668650

Nagoya Daini Red Cross Hospital, Nagoya

5148507

Mie University Hospital, Tsu

5658565

National Cardiovascular Center, Suita

6028026

Kyoto Second Red Cross Hospital, Kyoto

6068507

Kyoto University Hospital, Kyoto

6500017

Kobe University Hospital, Kobe

6500046

Kobe City General Hospital, Kobe

7408510

National Hospital Organization Iwakuni Clinical Center, Iwakuni

7558505

Yamaguchi University Hospital, Ube

8300011

Kurume University Hospital, Kurume

0418512

National Hospital Organization Hakodate National Hospital, Hakodate

0030804

National Hospital Organization Hokkaido Cancer Center, Sapporo

0208505

Iwate Medical University Hospital, Morioka

Sponsors
All Listed Sponsors
collaborator

Mitsubishi Tanabe Pharma Corporation

INDUSTRY

lead

Ministry of Health, Labour and Welfare, Japan

OTHER_GOV